Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.

Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.

Validation of In-House Kit-Like Synthesis of Ga-Trivehexin and Its Biodistribution for Targeting the Integrin αvβ6 Expressing Tumors.

Integrin αvβ6 has become an extremely promising theranostic target for precise delineation of fast-growing malignant cells in the recent years. The aim of the study was to validate the in-house kit-like synthesis of Ga-Trivehexin (integrin αvβ6) and to evaluate its uptake in patients with integrin αvβ6 expressing head and neck and pancreatic cancer. Ga-Trivehexin was synthesized by adding the variable amount of integrin αvβ6 (30-50 μg) to full volume (4-5 mL) Ga-68 in 0.